Amgen has gained a European marketing authorization for its biosimilar version of Abbvie’s anti-inflammatory drug adalimumab (Humira), making it the first European license for a biosimilar to adalimumab. Amgen’s product will be called biosimilar adalimumab (Amgevita).
Biosimilar adalimumab is approved for the following inflammatory conditions in adults:
It is also approved for the following pediatric conditions:
The approval comes from results of 2 phase 3 studies conducted in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis patients, each of which met their primary endpoint with no clinically meaningful differences to adalimumab, including safety and immunogenicity data.
Approval from the European Commission (EC) means Amgen can now market the drug across 28 countries across Europe. Other European Economic Area member nations, including Norway, Iceland and Liechtenstein, will take corresponding decisions based on the EC decision.
Called adalimumab-atto (Amjevita) in the United States, Amgen gained FDA approval in September 2016. However, pending legal issues have prevented market launch.
Global sales of Humira crossed $16 billion in 2016.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.